Key result
Pre-treatment estimated small dense LDL-C linked to ~24% higher CAD risk per SD in HeFH.
Why the study?
The clinical utility of estimated small-dense LDL-C (EsdLDL-C) in heterozygous familial hypercholesterolemia (HeFH), including its sex-specific associations with CAD prevalence and discriminative value beyond LDL-C, had not yet been evaluated.
Does pre-treatment estimated small-dense LDL cholesterol (EsdLDL-C) improve the discrimination and prediction of established coronary artery disease beyond standard LDL-C in adults with clinically diagnosed heterozygous familial hypercholesterolemia?
Cross-Sectional (n=3,276)
Yes
Does pre-treatment estimated small-dense LDL cholesterol (EsdLDL-C) improve the discrimination and prediction of established coronary artery disease beyond standard LDL-C in adults with clinically diagnosed heterozygous familial hypercholesterolemia?
In adults with clinically diagnosed heterozygous familial hypercholesterolemia, pre-treatment estimated small-dense LDL-C is independently associated with established CAD and offers superior discriminative value beyond standard LDL-C, particularly in women.
Answers are grounded in this paper and cite their sources.
Estimated small-dense LDL-C may aid CAD discrimination in heterozygous FH; leaves open incremental value beyond LDL-C in prospective studies.
AIM: Recent evidence reports good agreement between measured and estimated small-dense low-density lipoprotein cholesterol (EsdLDL-C) using a readily applicable formula. Its clinical utility in heterozygous familial hypercholesterolemia (HeFH) has not yet been evaluated. We aimed to evaluate the sex-specific associations of pre-treatment EsdLDL-C with coronary artery disease (CAD) prevalence in adult patients with HeFH and its discriminative value beyond LDL-C. METHODS: Data from consecutively recruited adults with a clinical diagnosis of HeFH from an ongoing registry (HELLAS-FH, n = 3,276) were analyzed. Patient demographics, lipid parameters, CAD risk factors, and CAD prevalence at registry enrollment were evaluated. EsdLDL-C was calculated at pre-treatment (i.e., before any hypolipidemic therapy initiation) using the Sampson equation. RESULTS: EsdLDL-C was associated with an increased prevalence of type 2 diabetes and hypertension, a higher body mass index and triglycerides, and lower high-density lipoprotein cholesterol. EsdLDL-C was also the strongest independent lipid-associated factor for CAD (OR: 1.24, p<0.001). This association was more pronounced in women (OR 1.57, p<0.001). EsdLDL-C showed higher CAD discrimination than LDL-C (AUC 0.611 vs. 0.522). Incorporating EsdLDL-C into the best discriminative model improved discriminative ability vs the core model (AUC 0.831 vs 0.828, p = 0.038) and overall model fit (ΔAIC) = -10.3). This incremental predictive value was driven predominantly by females (ΔAIC = -14.1; AUC 0.787 vs 0.769, p = 0.015). CONCLUSION: In a large sample of patients with clinical HeFH, EsdLDL-C was incrementally associated with CAD beyond LDL-C. This finding was more pronounced in women. The clinical utility of this readily available lipid marker as a risk enhancer should therefore be further investigated.
No takes yet. Share an insight, caveat, or question.
Delialis et al. (2026) conducted a cross-sectional in Heterozygous Familial Hypercholesterolemia (n=3,276). Pre-treatment estimated small dense LDL cholesterol (EsdLDL-C) vs. Per 1-SD increase in pre-treatment EsdLDL-C (and comparison with standard LDL-C) was evaluated on Prevalence of established coronary artery disease (CAD) (OR 1.24, 95% CI 1.10-1.40, p=<0.001). Pre-treatment estimated small dense LDL cholesterol was independently associated with established CAD in heterozygous FH, particularly in women.
Synapse has enriched 10 related papers. Consider them for comparative context: